Effexor XR (venlafaxine HCl) extended-release capsules are indicated for the treatment of depression, generalised anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) with or without agoraphobia in adults.
Teva Pharmaceutical has been awarded 180-day period of exclusive marketing rights for the drug for being the first company to file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the drug.
William Marth, president and CEO of Teva North America, said: “It is truly our pleasure to introduce our Venlafaxine product. Through the current patent settlement process, we are able to launch this product 7 years early.”